Fast Five Quiz: Adjuvant Therapy for HR+, HER2- Breast Cancer

Elwyn C. Cabebe, MD; Stefania Morganti, MD


January 11, 2023

Approximately 70%-80% of all breast cancers are hormone receptor–positive (HR+), with tumor cells expressing either the estrogen receptor (ER), progesterone receptor (PR), or both. Testing for human epidermal growth receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is undertaken at diagnosis to guide treatment decisions. More than 80% of HR+ tumors are HER2-negative (HER2-) so that HR+/HER2- breast cancer is the most common subtype of invasive breast cancer. Adjuvant therapy for breast cancer aims to treat micrometastatic disease. A cornerstone of treatment for HR+/HER2- breast cancer is adjuvant endocrine therapy (eg, aromatase inhibitors and/or tamoxifen with or without ovarian suppression).

How familiar are you with adjuvant therapy for this breast cancer subtype? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.